BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

Although targeting oncogenic mutations in the BRAF serine/threonine kinase with small molecule inhibitors can lead to significant clinical responses in melanoma, it fails to eradicate tumors in nearly all patients. Successful therapy will be aided by identification of intrinsic mechanisms that prote...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Haq, Rizwan, Yokoyama, Satoru, Hawryluk, Elena B., Jönsson, Göran B., Frederick, Dennie Tompers, McHenry, Kevin, Porter, Dale, Tran, Thanh-Nga, Love, Kevin T., Langer, Robert, Anderson, Daniel G., Garraway, Levi A., Duncan, Lyn McDivitt, Morton, Donald L., Hoon, Dave S. B., Wargo, Jennifer A., Song, Jun S., Fisher, David E.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: National Academy of Sciences 2013
विषय:
Biological Sciences
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3600451/
https://ncbi.nlm.nih.gov/pubmed/23447565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1205575110
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन